• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

CVS: 4 Approaches to Reduce The Cost Impact of Gene Therapies

by Jasmine Pennic 01/15/2020 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

While the life-changing and life-saving potential of gene therapies is tremendously exciting, finding ways to pay for these treatments is a significant challenge for families and payors. With prices for a single treatment as high as $2 million, many employers are struggling to find ways to offer coverage without bankrupting their health plans, or even their companies. Newly released CVS Health white paper outlines four key approaches that health plans and employers can utilize to reduce the cost impact of gene therapies. The promise of alleviating a significant amount of suffering could mean that gene therapies are cost effective — at the right price point. Gene therapy has shown tremendous promise for people living with genetic disorders. While these life-altering therapies are exciting, they are also come with high price tags, leaving us to ask – how can we pay for these expensive drugs? Defining Gene Therapy Gene therapies use a target gene that expresses protein products at a sufficient level to cure, or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European Medicines Agency has approved a few more than the FDA — and there are many more in the pipeline. Estimating the precise cost impact of gene therapies is very complicated and challenging. It is unclear how many patients with a particular condition may be treated with a given therapy or exactly how much the treatment will cost. To help plan sponsors estimate the impact of these treatments, CVS analyzed the projected cost in a newly released white paper based on: Publicly available information about therapies in development Likelihood of approval Estimated prevalence of those conditions Lowest estimated cumulative five-year cost impact based on a price of $1 million and 30 percent market penetration Highest estimated cumulative five-year cost impact based on a price of $2 million, and market penetration of 40 percent for ex vivo therapies, and 60 percent for in vivo therapies Today, there is not enough patient follow-up data yet to know whether they will truly be "cures" or if the diseases will eventually return. Even if they are not truly cures that are sustained over a patient’s lifespan, the promise of alleviating a significant amount of suffering could mean that gene therapies are cost effective — at the right price point. As it stands, the huge, initial costs are clouding that promise. Due to the potentially prohibitive costs, some employers are considering excluding ultra-high cost gene therapies from their plan benefit coverage. However, doing so might be short-sighted if the treatments are proven to be as truly effective long-term as they appear to be today. As a result, that can be a tough rationale to accept for plan sponsors facing a large, one-time burst of spending, here and now. To address the cost-access conundrum, CVS Health has developed a four-pronged strategy for health plans and employers to reduce the cost impact impact of gene therapies: Extend the National Medical Excellence (NME) Program Model – Address medical benefit costs associated with gene therapies by expanding NME program model to enable expert care coordination and keep costs in check. Evolve the Role of Specialty Pharmacy – Enable specialty pharmacies to purchase gene therapies directly from manufacturers to reduce cost impact across the drug supply chain. Implement Value-Based Contracting – Tie reimbursement to an expected outcome to minimize risk to payors and provide long-term real-world efficacy data. Create Financial Protection Plans – Minimize risk for smaller companies and organizations by creating new insurance products that ensure access and protect the financial viability of their benefit plan. For more information on approaches to reduce the cost impact of gene therapies, download the full CVS report here.

– While the life-changing and life-saving potential of gene therapies is tremendously exciting, finding ways to pay for these treatments is a significant challenge for families and payors.

– With prices for a single treatment as high as $2 million, many employers are struggling to find ways to offer coverage without bankrupting their health plans, or even their companies.

– Newly released CVS Health white paper outlines four key approaches that health plans and employers can utilize to reduce the cost impact of gene therapies.

The promise of alleviating a significant amount of suffering could mean that gene therapies are cost-effective — at the right price point. Gene therapy has shown tremendous promise for people living with genetic disorders. While these life-altering therapies are exciting, they are also come with high price tags, leaving us to ask – how can we pay for these expensive drugs?

Defining Gene Therapy

Gene therapies use a target gene that expresses protein products at a sufficient level to cure or at least ameliorate, a disease caused by a genetic defect. So far, the U.S. Food and Drug Administration (FDA) has approved a handful of gene therapies to treat serious diseases that were previously untreatable except through supportive measures. The European Medicines Agency has approved a few more than the FDA — and there are many more in the pipeline.

Estimating the precise cost impact of gene therapies is very complicated and challenging. It is unclear how many patients with a particular condition may be treated with a given therapy or exactly how much the treatment will cost.

To help plan sponsors estimate the impact of these treatments, CVS analyzed the projected cost in a newly released white paper based on

– Publicly available information about therapies in development

– Likelihood of approval Estimated prevalence of those conditions

–Lowest estimated cumulative five-year cost impact based on a price of $1 million and 30 percent market penetration

– Highest estimated cumulative five-year cost impact based on a price of $2 million, and market penetration of 40 percent for ex vivo therapies, and 60 percent for in vivo therapies

Today, there is not enough patient follow-up data yet to know whether they will truly be “cures” or if the diseases will eventually return. Even if they are not truly cures that are sustained over a patient’s lifespan, the promise of alleviating a significant amount of suffering could mean that gene therapies are cost-effective — at the right price point.

As it stands, the huge, initial costs are clouding that promise. Due to the potentially prohibitive costs, some employers are considering excluding ultra-high cost gene therapies from their plan benefit coverage. However, doing so might be short-sighted if the treatments are proven to be as truly effective long-term as they appear to be today. As a result, that can be a tough rationale to accept for plan sponsors facing a large, one-time burst of spending, here and now.

To address the cost-access conundrum, CVS Health has developed a four-pronged strategy for health plans and employers to reduce the cost impact of gene therapies:

1. Extend the National Medical Excellence (NME) Program Model – Address medical benefit costs associated with gene therapies by expanding NME program model to enable expert care coordination and keep costs in check. 

2. Evolve the Role of Specialty Pharmacy – Enable specialty pharmacies to purchase gene therapies directly from manufacturers to reduce cost impact across the drug supply chain.

3. Implement Value-Based Contracting – Tie reimbursement to an expected outcome to minimize risk to payors and provide long-term real-world efficacy data.

4. Create Financial Protection Plans – Minimize risk for smaller companies and organizations by creating new insurance products that ensure access and protect the financial viability of their benefit plan.  

For more information on approaches to reduce the cost impact of gene therapies, download the full CVS report here.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

How eClinicalWorks Agentic AI Is Helping Revenue Cycle Leaders Improve Financial Performance

Most-Read

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

Innovaccer-CHIME 2030 Survey Reveals AI Will Automate Nearly Two-Thirds of Administrative Work and Do 3x the Work With the Same Staff

CB Insights’ 2026 Digital Health 50 Reveals How Agentic AI Is Becoming the Clinical Provider and Medication Access Engine

Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

M&A: Oura Acquires Counsel Health for $625M: Scaling Continuous Biometrics into On-Demand Medical Care

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

WittKieffer 2026 Healthcare CIO Survey: 82% Sit on Executive Teams, Yet Only 36% Have Formal Succession Plans

CVS Rebrands Health Services Segment, Launches Model for Retail Pharmacy Reimbursement

CVS Health Formalizes Tax-Free Split-Off to Carve Out CVS Pharmacy by 2028

SAMHSA and ONC Invest $20M in Behavioral Health IT Initiative

ONC Finalizes HTI-5 Deregulatory Rule to Cut $1.55B in Health IT Compliance and Accelerate FHIR APIs

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Redesign Health Merges with Sheba Medical Center’s ARC Global and Agrees to Acquire AVIA

Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Sword Acquires Headspace in All-Cash Deal Worth Up to $300M to Unify Physical and Mental AI Care

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

M&A: Francisco Partners to Acquire Weave in $650M Take-Private Deal

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Epic Launches One-Click Care Everywhere Diagnostic Image Exchange

Secondary Sidebar

Footer

Company

  • About Us
  • 2026 Editorial Calendar
  • Advertise with Us
  • Reprints and Permissions
  • Op-Ed Submission Guidelines
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2026. HIT Consultant Media. All Rights Reserved. Privacy Policy |